Department of Obstetrics & Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ultrasound Obstet Gynecol. 2013 Jul;42(1):84-92. doi: 10.1002/uog.11223.
To investigate, using three-dimensional power Doppler ultrasound (3D-PDU), alterations in cervical intratumoral vascularization during and after radiotherapy.
Between 2004 and 2009 we enrolled into the study 37 patients with FIGO Stages IB1-IIB cervical carcinoma who were undergoing radiotherapy. Serial 3D-PDU scans were performed during treatment, providing ultrasonographic measurement of tumor size, vascularization index, flow index and vascularization flow index, as well as monthly for 3 months post-treatment and tri-monthly thereafter, until vascularity was undetectable on two consecutive occasions. Physical examination, cervical cytology and serum marker evaluation were performed every 3-6 months for the first 5 years following treatment. Patients evaluated after a 2-year tumor-free interval and those with clinically assessed positive findings at follow-up underwent 3D-PDU to detect possible local disease.
A total of 329 3D-PDU scans were performed in the 37 women. Cervical tumors and intratumoral vascularization disappeared within 3 months following radiotherapy, except in one patient with persistent disease. Nine patients had disease relapse, in four of whom the recurrence was local. In three of these four, there was recurrence of tumor and vascularization after a complete response. At follow-up, 3D-PDU detected local disease with 75.0% sensitivity and 98.5% specificity, while serum markers detected local disease among 34 patients with squamous cell carcinoma with 20.0% sensitivity and 77.3% specificity.
Compared with serum markers in cervical squamous cell carcinoma, 3D-PDU has higher sensitivity and specificity for detecting local recurrence or persistence in cervical carcinoma. Thus, 3D-PDU combined with clinical assessment may be a new and safe method for monitoring radiotherapy treatment response and detecting local recurrence.
利用三维能量多普勒超声(3D-PDU)研究宫颈癌放疗过程中和放疗后肿瘤内血管变化。
2004 年至 2009 年,我们共招募了 37 名 FIGO 分期为 IB1-IIB 的宫颈癌患者,这些患者正在接受放疗。在治疗过程中进行了连续的 3D-PDU 扫描,提供了肿瘤大小、血管指数、血流指数和血管化血流指数的超声测量,以及治疗后 3 个月每月一次,此后每 3 个月一次,直到两次连续检查均无法检测到血管。治疗后前 5 年,每 3-6 个月进行体格检查、宫颈细胞学和血清标志物评估。在 2 年无肿瘤间隔后评估的患者和随访时临床评估阳性的患者进行 3D-PDU 以检测可能的局部疾病。
37 名女性共进行了 329 次 3D-PDU 扫描。除 1 例持续性疾病患者外,宫颈癌和肿瘤内血管在放疗后 3 个月内消失。9 名患者疾病复发,其中 4 例为局部复发。在这 4 例中有 3 例在完全缓解后肿瘤和血管复发。在随访中,3D-PDU 检测局部疾病的敏感性为 75.0%,特异性为 98.5%,而在 34 例鳞状细胞癌患者中,血清标志物检测局部疾病的敏感性为 20.0%,特异性为 77.3%。
与宫颈鳞状细胞癌的血清标志物相比,3D-PDU 检测宫颈癌局部复发或持续存在的敏感性和特异性更高。因此,3D-PDU 结合临床评估可能是监测放疗治疗反应和检测局部复发的一种新的安全方法。